Journal of Neuro-Oncology

, Volume 58, Issue 1, pp 21–32 | Cite as

Lysosomal Enzymes, Cathepsins in Brain Tumour Invasion

  • Nataša Levičar
  • Tadej Strojnik
  • Janko Kos
  • Ricardo A. Dewey
  • Geoffrey J. Pilkington
  • Tamara T. Lah


The expression patterns of different classes of peptidases in central nervous system (CNS) tumours have been most extensively studied in astrocytomas and meningiomas. Although the two types of tumours are very different in most respects, both may invade locally into normal brain. This process of invasion includes increased synthesis and secretion of lysosomal proteolytic enzymes – cathepsins.

Aspartic endopeptidase cathepsin (Cat) D levels were found to be elevated in high-grade astrocytoma and partial inhibition of glioblastoma cell invasion by anti-Cat D antibody suggests that the enzyme activity is involved in the invasion process. Several studies on cysteine endopeptidase (CP) Cat B in gliomas agreed that transcript abundance, protein level and activity of Cat B increased in high-grade astrocytoma cultures compared with low-grade astrocytoma cultures and normal brain. Moreover, in glioma biopsies Cat B levels correlated with evidence of clinical invasion and it has been demonstrated that Cat B both in tumour cells and in endothelial cells can serve as a new biological marker for prognosis in glioblastoma patients. A high level of Cat B protein was also a diagnostic marker for invasive types of meningioma, distinguishing between histomorphologically benign, but invasive meningiomas and noninvasive, so-called clear–benign meningiomas. Cat L was also significantly increased in high-grade astrocytoma compared with low-grade astrocytoma and normal brain. Specific Cat L antibodies and antisense Cat L RNA transfection significantly lowered glioblastoma cell invasion. In meningioma, Cat L was a less-significant marker of invasion than Cat B. In contrast to cathepsins, the activities of endogenous cysteine peptidase inhibitors (CPIs), including stefins, cystatins and kininogens, were significantly higher in benign and atypical meningioma cell extracts than in malignant meningioma, and low-grade compared to high-grade astrocytoma. However, very low levels of stefins A and B were found in meningioma and glioblastoma tissues. Further studies on the expression levels and balance between cysteine endopeptidases (CPs) and CPIs would improve the clinical application of cathepsins in prognosis, which would lead to more-informed therapeutic strategies.

angiogenesis cathepsins cystatins glioma invasion meningioma stefins 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    World Health Organization Classification of Tumours. In: Kleinhues P, Cavenee WK (eds) Pathology and Genetics of Tumours of the Nervous System. IARC Press, Lyon, 2000Google Scholar
  2. 2.
    Frosch BA, Sloane BF: The role of proteolytic enzymes in brain tumour infiltration. In: Mikkelsen T, Bjerkvig R, Laerum OD, Rosenbaum ML (eds) Brain Tumour Invasion: Biological, Clinical and Therapeutic Considerations. Wiley-Liss, New York, 1998, pp 275-300Google Scholar
  3. 3.
    Tonn J-Ch, Bernstein JJ, Goldbrunner: Processes of glioma invasion. Int J Neurosci 17: 411, 1999Google Scholar
  4. 4.
    Schiffer D, Cavalla P, Pilkington GJ: Proliferative properties of malignant brain tumors. In Mikkelsen T, Bjerkvig R, Laerum OD, Rosenbaum ML (eds) Brain Tumour Invasion: Biological, Clinical and Therapeutic Considerations. New York, Wiley-Liss, 1998, pp 161-184Google Scholar
  5. 5.
    Pedersen PH, Nygaard SJT, Baardsen R, Tysnes BB, Engebraaten O, Bjerkvig R: Glioma cell invasion studied in organotypic coculture models. In: Mikkelsen T, Bjerkvig R, Laerum OD, Rosenbaum ML (eds) Brain Tumour Invasion: Biological, Clinical and Therapeutic Considerations. New York, Wiley-Liss, 1998, pp 219-230Google Scholar
  6. 6.
    Pilkington GJ: The paradox of neoplastic glial cell invasion of the brain and apparent metastatic failure. Anticancer Res 17: 4103-4106, 1997Google Scholar
  7. 7.
    De Ridder L: Meningiomas: Behavior in vivo and in vitro. In: Mikkelsen T, Bjerkvig R, Laerum OD, Rosenbaum ML (eds) Brain Tumour Invasion: Biological, Clinical and Therapeutic Considerations. New York, Wiley-Liss, 1998, pp 185-199Google Scholar
  8. 8.
    Louis DN, Scheithauer BW, Budka H, von Deimling, Kepes JJ. Meningiomas. In: Kleinhues P, Cavenee WK (eds) Pathology and Genetics of Tumours of the Nervous System. IARC Press, Lyon, 2000, pp 175-193Google Scholar
  9. 9.
    Nakasu S, Hirano A, Llena J, Shimura T, Honda J: Interface between the meningioma and the brain. Surg Neurol 32: 206-212, 1989Google Scholar
  10. 10.
    Strojnik T, Kos J, Židanik B, Lah TT: Cathepsins B and L are markers for clinically invasive types of meningiomas. Neurosurgery 48: 598-605, 2001Google Scholar
  11. 11.
    Wyke JA: Overview-burgeoning promise in metastasis research. Eur J Cancer 36: 1589-1594, 2000Google Scholar
  12. 12.
    Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991Google Scholar
  13. 13.
    Rawlings ND, Barrett AJ: MEROPS: the peptidase database. Nucleic Acid Res 27(1): 325-337, 1999Google Scholar
  14. 14.
    Sloane BF, Moin K, Lah TT: Regulation of lysosomal endopeptidases in malignant neoplasia. In: Pretlow TG, Pretlow TP (eds) Biochemical and Molecular Aspects of Selected Cancers. Academic Press, New York, 1994, pp 411-472Google Scholar
  15. 15.
    Duffy MJ: Proteases as prognostic markers in cancer. Minireview. Clin Cancer Res 2: 613-618, 1996Google Scholar
  16. 16.
    Kos J, Lah TT: Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (Review). Oncol Rep 5: 1349-1361, 1998Google Scholar
  17. 17.
    Schmitt M, Janicke F, Graeff F: Tumour-associated proteases. Fibrinolysis 6(Suppl 4): 3-26, 1992Google Scholar
  18. 18.
    Koblinski JE, Ahram M, Sloane BF: Unraveling the role of proteases in cancer. Clin Chim Acta 291: 113-135, 2000Google Scholar
  19. 19.
    Turk B, Turk D, Turk V: Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 1477: 98-111, 2000Google Scholar
  20. 20.
    Laurent V, Farnoud MR, Lucas A, Rougeot C, Garcia M, Rochefort H: Endocytosis of pro-cathepsin D into breast cancer cells is mostly independent of mannose-6-phosphate receptors. J Cell Sci 111: 2539-2549, 1998Google Scholar
  21. 21.
    Frosch BA, Berquin I, Emmert-Buck MR, Moin K, Sloane BF: Molecular regulation, membrane association and secretion of tumour cathepsin B. APMIS 107: 28-37, 1999Google Scholar
  22. 22.
    Demchik LL, Sameni M, Nelson K, Mikkelsen T, Sloane BF: Cathepsin B and glioma invasion. Int J Dev Neurosci 17(5-6): 483-494, 1999Google Scholar
  23. 23.
    Lah TT, Buck MR, Honn KV, Crissman JF, Rao NC, Liotta LA, Sloane BF: Degradation of laminin by human tumour cathepsin B. Clin Expl Metastasis 7: 461-468, 1998Google Scholar
  24. 24.
    Buck MR, Karustis DG, Day NA, Honn KV, Sloane BF: Degradation of extracellular matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J 282: 273-278, 1992Google Scholar
  25. 25.
    Rozman J, Stojan J, Kuhelj R, Turk V, Turk B: Autocatalytic processing of recombinant human procathepsin B is a bimolecular process. FEBS Lett 459: 358-362, 1999Google Scholar
  26. 26.
    Cavailles V, Augereau P, Rochefort H: Cathepsin D gene is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription in breast cancer cells. Proc Natl Acad Sci USA 90(1): 203-207, 1993Google Scholar
  27. 27.
    Berquin IM, Sloane BF: Cysteine proteases and tumour progression. Persp Drug Discovery Design 2: 371-388, 1994Google Scholar
  28. 28.
    Gong Q, Chan SJ, Bajkowski AS, Steiner DF, Frankfater A: Characterisation of the cathepsin B gene and multiple RNAs in human tissues: Evidence for alternative splicing of cathepsin B pre-mRNA. DNA Cell Biol 12: 299-309, 1993Google Scholar
  29. 29.
    Rescheleit DK, Rommerskirch WJ, Wiederanders B: Sequence analysis and distribution of two new human cathepsin L splicing variants. FEBS Lett 394: 345-348, 1996Google Scholar
  30. 30.
    Rochefort H, Garcia M, Glondu M, Laurent V, Liaudet E, Rey JM, Roger P: Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin Chem Acta 291: 157-170, 2000Google Scholar
  31. 31.
    Lah TT, Kos J: Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol Chem 379: 125-130, 1998Google Scholar
  32. 32.
    Kos J, Nielsen H-J, Krašovec M, Christensen OJ, Cimerman N, Stephen RW, Brunner N: Prognostic values of cathepsin B and carcioembrionic antigen in sera of patients with colorectal carcinoma. Clin Cancer Res 4: 1511-1516, 1998Google Scholar
  33. 33.
    Kos J, Štabuc B, Schweiger A, Krašovec M, Cimerman N, Kopitar-Jerala N, Vrhovec I: Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res 3: 1815-1822, 1997Google Scholar
  34. 34.
    Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossman H, Koester A, Hess B, Evers M, Von Figura K, Peters C: Mice defficient for the lysosomal proteinase cathepsin exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J 14: 3599-3608, 1995Google Scholar
  35. 35.
    Bever TC Jr, Snyder S, Enders RO, Morgan KD, Postlethwaite A, Whitacker JN: Activation of astrocytic lysosomal proteinase by factors released by mononuclear leukocytes. Neurochem Res 14(1): 37-41, 1989Google Scholar
  36. 36.
    Chopra VS, Moozar KL, Mehindate K, Schipper HM: Acellular stress model for the differential expression of glial lysosomal cathepsins in the ageing nervous system. Exp Neurol 147: 221-228, 1997Google Scholar
  37. 37.
    Callahan LM, Vaules WA, Coleman PD: Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles. J Neuropathol Exp Neurol 58(3): 275-287, 1999Google Scholar
  38. 38.
    Isahara K, Ohsawa Y, Kanamori S, Shibata M, Waguri S, Sato N, Gotow T, Watanabe T, Momoi T, Urase K, Kominami E, Uchiyama Y: Regulation of a novel pathway for cell death by lysosomal aspartic and cysteine proteinases. Neuroscience 91(1): 233-249, 1999Google Scholar
  39. 39.
    Robson DK, Ironside JW, Reid WA, Bogue PR: Immunolocalization of cathepsin D in the human central nervous system and central nervous system neoplasms. Neuropathol Appl Neurobiol 16: 39-44, 1990Google Scholar
  40. 40.
    Kruczynski A, Salmon I, Camby I, Limouzy A, Rombaut K, Pastels J-L, Delsol G, Brotchi J, Kiss R: The characterisation of nuclear DNA content, the proliferative activity and the immunohistochemical expression of GFAP, VIM, LEU-7, S-100, p53 and cathepsin D in human glioblastoma multiformes (hGBMs) versus human GBM cell lines grafted into brains of nude mice. Int J Oncol 6: 473-481, 1995Google Scholar
  41. 41.
    Sivaparvathi M, Sawaya R, Chintala SK, Go Y, Gokaslan ZL, Rao JS: Expression of cathepsin D during the progression of human gliomas. Neurosci Lett 208(3): 171-174, 1996Google Scholar
  42. 42.
    Tews DS, Nissen A: Expression of adhesion factors and degrading proteins in primary and secondary glioblastoma and their precursor tumors. Invasion Metastasis 18(5-6): 271-284, 1998-1999Google Scholar
  43. 43.
    Warich M, Von Bossanyi P, Dietzmann K: Expression of cathepsin D in human astrocytic neoplasias. Gen Diagn Pathol 141: 93-93, 1995Google Scholar
  44. 44.
    Lenarčič B, Bevec T: Thyropins - new structurally related proteinase inhibitors. Biol Chem 379: 105-111, 1998Google Scholar
  45. 45.
    Chapman HA, Riese RJ, Shi G-P: Emerging roles for cysteine proteases in human biology. Ann Rev Physiol 59: 63-88, 1997Google Scholar
  46. 46.
    Brix K, Lemansky P, Herzog V: Evidence for extracellular acting cathepsins mediating thyroid hormone liberation in thyroid epithelial cells. Endocrinology 137: 20198-20204, 1996Google Scholar
  47. 47.
    Kobayashi H, Schmitt M, Goretzky L, Chucholowski N, Calvete J, Kramer M, Guncler WA, Janicke F, Graeff H: Cathepsin B efficiently inactivates the soluble and tumour cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). J Biol Chem 266: 5147-5152, 1990Google Scholar
  48. 48.
    Calkins CC, Sloane BF: Mammalian cysteine proteinase inhibitors: biochemical properties and possible role in tumour progression. Biol Chem Hoppe-Seyler's 376: 71-80, 1995Google Scholar
  49. 49.
    Sloane BF, Moin K, Sameni M, Tait LR, Rozhin J, Ziegler G: Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene. J Cell Sci 107: 798-804, 1994Google Scholar
  50. 50.
    Kang JX, Bell J, Leaf A, Berad RL, Chandraratna RAS: Retinoic acid alters the intracellular trafficking of the mannose-6-phosphate/insulin-like growth factor II receptor and lysosomal enzymes. Proc Natl Acad Sci USA 95: 13687-13691, 1998Google Scholar
  51. 51.
    Lah TT, Calaf G, Kalman E, Shinde G, Somers R, Estrada S, Salero E, Russo J, Jarocz, D, Zabrecky J, Daskal I: Differential regulation of cathepsins D, B and L in transformed human breast epithelial cells (HBEC) with increased invasivness. Breast Cancer Res Treat 39: 221-233, 1996Google Scholar
  52. 52.
    Banati RB, Rothe G, Valet G, Kreutzberg GW: Detection of lysosomal cysteine proteinases in microglia: flow cytometric measurements and histochemical localization of cathepsins B and L. Glia 7: 183-191, 1993Google Scholar
  53. 53.
    Ryan RE, Sloane BF, Sameni M, Wood PL: Microglial cathepsin B: an immunological examination of cellular and secreted species. J Neurochem 65: 1035-1045, 1995Google Scholar
  54. 54.
    Mantle D, Falkous G, Ishiura S, Perry RH, Perry EK: Comparison of cathepsin protease activities in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease. J Neurol Sci 131: 65-70, 1995Google Scholar
  55. 55.
    Cataldo AM, Nixon RA: Enyzmatically active lysosomal proteases are associated with amyloid deposits in Alzheimer's brain. Proc Natl Acad Sci USA 87: 3861-3865, 1990Google Scholar
  56. 56.
    Lemere CA, Munger JS, Shi G-P, Natkin L, Haasa Ch, Champan HA, Selkoe DJ: The lysosomal cysteine proteasse cathepsin S is increased in Alzheimer's disease and Down syndrome brain. Am J Pathol 146: 8448-8860, 1995Google Scholar
  57. 57.
    McCormick D: Secretion of Cat B by human gliomas in vitro. Neuropathol Appl Neurobiol 19: 146-151, 1993Google Scholar
  58. 58.
    Rempel SA, Rosenblum ML, Mikkelsen T, Yan P-S, Ellis KD, Golembieski WA, Sameni M, Rozhin J, Ziegler G, Sloane BF: Cathepsin B expression and localization in glioma progression and invasion. Cancer Res 54: 6027-6031, 1994Google Scholar
  59. 59.
    Sivaparvathi M, Sawaya R, Wang SW, Rayford A, Yamamoto M, Liotta LA, Nicoloson GL, Rao JS: Overexpression and localization of Cat B during the progression of human gliomas. Clin Exp Metastasis 13: 49-56, 1995Google Scholar
  60. 60.
    Mikkelsen T, Yan PS, Ho KL, Sameni M, Sloane BF, Rosenblum ML: Immunolocalization of Cat B in human glioma: implications for tumour invasion and angiogenesis. J Neurosurg 83: 285-290, 1995Google Scholar
  61. 61.
    Strojnik T, Kos J, Židanik B, Golouh R, Lah TT: Cathepsin B immunohistochemical staining in tumour and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin Cancer Res 5: 559-567, 1999Google Scholar
  62. 62.
    Lah TT, Strojnik T, Levičar N, Bervar A, Zajc I, Pilkington G, Kos J: Clinical and experimental studies of cysteine cathepsins and their inhibitors in human brain tumors. Int J Biol Markers 15: 90-93, 2000Google Scholar
  63. 63.
    Levičar N, Dewey R, Kos J, Pilkington JG, Lah TT: Full length Cathepsin L antisense RNA induces downregulation of its protein levels, inhibiting brain tumour invasion in vitro. In: Book of Abstracts of International Conference on Cysteine Proteinases and their Inhibitors. The New Millenium, Slovenia, September 2000, p 92Google Scholar
  64. 64.
    Dalet-Fumeron V, Boudennah L, Pagano M: Binding of the cysteine proteinases papain and cathepsin B-like to coated laminin: use of synthetic peptides from laminin and from laminin binding region of the beta 1 integrin subunit to characterize the binding site. Arch Biochem Biophys 15: 358(2): 283-290, 1998Google Scholar
  65. 65.
    Rooprai HK, Liyanage K, Robinson SFD, Kandanearatchi A, Dean AF, Pilkington GJ: Extracellular matrix-modulated differential invasion of human meningioma cell lines in vitro. Neurosci Lett 263: 214-216, 1999Google Scholar
  66. 66.
    Sivaparvathi M, Yamamoto M, Nicolson GL, Gokaslan ZL, Fuller GN, Liotta LA, Sawaya R, Rao JS: Expression and immunohistochemical localization of cathepsin L during the progression of human gliomas. Clin Exp Metastasis 14(1): 27-34, 1996Google Scholar
  67. 67.
    Amberger VR, Hensel T, Ogata N, Schwab ME: Spreading and migration of human glioma and rat C6 cells on central nervous system myelin in vitro is correlated with tumour malignancy and involves a metalloproteolytic activity. Cancer Res 58: 149-158, 1998Google Scholar
  68. 68.
    Sivaparvathi M, Sawaya R, Gokaslan ZL, Chintala SK, Rao JS, Chintala SK: Expression and the role of cathepsin H in human glioma progression and invasion. Cancer Lett 104(1): 121-126, 1996Google Scholar
  69. 69.
    Gibson D, Mulligan K, Pinder D, Trimble A, Shi GP, Walker N, McCormick D: Extracellular cathepsin S activity is increased in high grade astrocytoma in vitro. In: Book of Abstracts of International Conference on Cysteine Proteinases and Their Inhibitors: The New Millennium, Portorož, Slovenia, September 2000, p 94Google Scholar
  70. 70.
    Bjarnadottir M, Wulff BS, Sameni M, Sloane BF, Keppler D, Grubb A, Abrahamson M: Intracellular accumulation of the amyloidogenic L68Q variant of human cystatin C in NIH/3T3 cells. Mol Pathol 51: 317-326, 1998Google Scholar
  71. 71.
    Lah TT, Kokalj-Kunovar M, Štrukelj B, Pungerčar J, Maganja D-B, Drobnič-Košorok M, Kastelic L, Babnik J, Golouh R, Turk V: Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int J Cancer 50: 36-44, 1992Google Scholar
  72. 72.
    Calkins CC, Sameni M, Koblinski J, Sloane BF, Moin K: Differential localization of cysteine protease inhibitors and a target cysteine protease cathepsin B by immuno-confocal microscopy. J Histochem Cytochem 46: 745-751, 1998Google Scholar
  73. 73.
    Sivaparvathi M, McCutcheon I, Sawaya R, Nicolson GL, Rao JS: Expression of cysteine protease inhibitors in human gliomas and meningiomas. Clin Exp Metastasis 14: 344-350, 1996Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Nataša Levičar
    • 1
  • Tadej Strojnik
    • 2
  • Janko Kos
    • 3
    • 4
  • Ricardo A. Dewey
    • 5
  • Geoffrey J. Pilkington
    • 5
  • Tamara T. Lah
    • 1
  1. 1.Department of Genetic Toxicology and Cancer BiologyNational Institute of BiologyLjubljana
  2. 2.Department of NeurosurgeryMaribor Teaching HospitalMaribor
  3. 3.Department of Biochemistry and Molecular BiologyJožef Stefan InstituteLjubljana
  4. 4.Department of Biochemical Research and Drug DesignKrkaLjubljanaSlovenia
  5. 5.Department of Neuropathology, Experimental Neuro-Oncology Group, Institute of PsychiatryKing's College LondonLondon, UK

Personalised recommendations